Nimotuzumab Injection

DRUG4 trials

Conditions

Head & Neck CancerHead and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC)Nasopharyngeal CarcinomaNeoadjuvant TherapyRefractory Metastatic Colorectal CancerUterine Cervical Neoplasms

Phase 2

Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

Active, not recruitingNCT06771596

Cancer Institute and Hospital, Chinese Academy of Medical SciencesUterine Cervical Neoplasms

Start: 2021-05-12End: 2025-09-30Updated: 2025-01-13

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

RecruitingNCT07601737

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineHead and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer +1

Start: 2026-04-20End: 2030-04-30Target: 182Updated: 2026-05-22

Phase 3

Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

Not yet recruitingNCT06343116

Biotech Pharmaceutical Co., Ltd.Refractory Metastatic Colorectal Cancer

Start: 2024-04-30End: 2027-04-30Target: 420Updated: 2024-04-02

Phase 4

Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma

NCT02293356

Biotech Pharmaceutical Co., Ltd.Nasopharyngeal Carcinoma

Start: 2015-08-31End: 2017-12-31Target: 2000Updated: 2015-08-19

Related Papers

Nimotuzumab with chemoradiotherapy for newly diagnosed, high-risk, locally advanced squamous cervical cancer (CC11): A prospective single-arm phase II study.